Ixazomib in Combination with Cyclophosphamide/Dexamethasone or Lenalidomide/Dexamethasone

Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Noopur Raje, MD (2/10/16)

Dimopoulos MA et al. Randomized phase 2 study of the all-oral combination of investigational proteasome inhibitor (PI) ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible (NCT02046070). Proc ASH 2015;Abstract 26.

Moreau P et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM): The phase 3 Tourmaline-MM1 study (NCT01564537). Proc ASH 2015;Abstract 727.

Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.